NCT01554163View on ClinicalTrials.gov

Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

239

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Osteoarthritis of the Knee
Interventions
DRUG

Etoricoxib 30 mg

Etoricoxib 30 mg tablet once daily for 12 weeks.

DRUG

Celecoxib 200 mg

Celecoxib 200 mg once daily for 12 weeks

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT01554163 - Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis | Biotech Hunter | Biotech Hunter